Clarity Pharmaceuticals Advances Radiopharmaceutical Diagnostics
Clarity Pharmaceuticals Ltd. (AU:CU6) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Clarity Pharmaceuticals has successfully completed patient assessments for its Phase II DISCO trial, which evaluates the 64Cu-SARTATE imaging product in diagnosing neuroendocrine tumors. The trial demonstrated improved lesion detection using 64Cu-SARTATE due to its longer half-life compared to existing isotopes, potentially offering significant advancements in cancer diagnostics. As Clarity prepares for a Phase III trial, the results could pave the way for new, more effective diagnostic tools in the radiopharmaceutical sector.
For further insights into AU:CU6 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.